Cantourage Group (HIGH) investor relations material

Investment highlights and market position

• Profitable, asset-light, and capital-efficient business model with a strong presence in Germany, UK, and Poland, and plans for further European expansion.

• Diversified product portfolio addresses a wide range of patient needs and medical indications.

• International markets contributed 54% of Q2 revenue, up from 16%, reflecting successful geographic diversification.

• Flexible and agile operating model enables swift adaptation to changing market demands.

Market dynamics and growth drivers

• Medical cannabis markets in Europe are rapidly growing, with Germany, UK, and Poland as key markets.

• Market penetration remains low, indicating significant growth potential; Germany (<5%), UK (<0.5%), Poland (<5%).

• Key growth drivers include simplified prescribing, telemedicine enablement, and broader product availability.

• Regulatory frameworks in core markets support long-term growth, with recent reforms impacting reimbursement pathways.

Product and service innovation

• Broad product range includes dried flowers, cannabidiol and dronabinol APIs, and solutions.

• Multi-brand strategy and revenue-sharing model with growers enhance product diversity and flexibility.

• Telemedicine platforms in Germany and UK streamline patient access and prescription processes.

• Data-driven approach leverages insights from sales and telemedicine to inform product launches and R&D.